Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19022712 | INFLUENZA VACCINE | January 2025 | May 2025 | Allow | 4 | 0 | 0 | No | No |
| 19007447 | METHODS OF TARGETED DELIVERY TO A HOST USING A CARRIER | December 2024 | May 2025 | Allow | 5 | 0 | 0 | No | No |
| 18865515 | FUSION PROTEIN AND USE THEREOF | November 2024 | March 2025 | Allow | 4 | 0 | 0 | No | No |
| 18936852 | METHODS OF FABRICATING CARRIERS FOR TARGETED DELIVERY TO A HOST | November 2024 | April 2025 | Allow | 5 | 1 | 0 | No | No |
| 18915537 | ENGINEERED MUSCLE TARGETING COMPOSITIONS | October 2024 | May 2025 | Allow | 7 | 0 | 1 | No | No |
| 18801143 | NUCLEIC ACID VACCINES | August 2024 | January 2025 | Allow | 5 | 1 | 0 | No | No |
| 18801174 | NUCLEIC ACID VACCINES | August 2024 | March 2025 | Allow | 7 | 1 | 0 | No | No |
| 18742851 | NOVEL PORCINE ROTAVIRUS | June 2024 | July 2025 | Abandon | 14 | 1 | 0 | No | No |
| 18734010 | ADOPTIVE CELLULAR THERAPY | June 2024 | May 2025 | Allow | 12 | 1 | 0 | No | No |
| 18734520 | MONOCLONAL ANTIBODIES DIRECTED AGAINST TRIMERIC FORMS OF THE HIV-1 ENVELOPE GLYCOPROTEIN WITH BROAD AND POTENT NEUTRALIZING ACTIVITY | June 2024 | January 2025 | Allow | 8 | 0 | 0 | No | No |
| 18731059 | METHOD OF ASSESSING RISK OF PML | May 2024 | April 2025 | Allow | 11 | 1 | 0 | No | No |
| 18662436 | CHIMERIC INFLUENZA VACCINES | May 2024 | July 2024 | Allow | 2 | 0 | 0 | No | No |
| 18659530 | VACCINES AND IMMUNOTHERAPEUTICS USING IL-28 AND COMPOSITIONS AND METHODS OF USING THE SAME | May 2024 | August 2025 | Abandon | 15 | 1 | 0 | No | No |
| 18651541 | USE OF TREM-1 INHIBITORS FOR TREATMENT, ELIMINATION AND ERADICATION OF HIV-1 INFECTION | April 2024 | July 2025 | Abandon | 15 | 1 | 0 | No | No |
| 18639558 | METHOD FOR INACTIVATING ZIKA VIRUS AND FOR DETERMINING THE COMPLETENESS OF INACTIVATION | April 2024 | August 2025 | Abandon | 16 | 1 | 0 | No | No |
| 18630437 | ANTIBODY NEUTRALIZING HUMAN RESPIRATORY SYNCYTIAL VIRUS | April 2024 | March 2025 | Allow | 11 | 1 | 0 | No | No |
| 18624929 | Adenoviral Vector | April 2024 | March 2025 | Allow | 12 | 1 | 0 | No | No |
| 18594435 | Multi-Epitope Vaccine for the Treatment of Alzheimer's Disease | March 2024 | December 2024 | Allow | 9 | 0 | 0 | No | No |
| 18414053 | VACCINE FOR USE IN THE PROPHYLAXIS AND/OR TREATMENT OF A DISEASE | January 2024 | November 2024 | Allow | 10 | 0 | 0 | No | No |
| 18402546 | VIRUS-INSPIRED COMPOSITIONS AND METHODS OF REDIRECTING PREEXISTING IMMUNE RESPONSES USING THE SAME FOR TREATMENT OF CANCER | January 2024 | February 2025 | Allow | 14 | 1 | 0 | No | No |
| 18392463 | VLP-BASED BIVALENT EBOLA VACCINES AND METHODS OF MAKING AND USING SAME | December 2023 | January 2025 | Allow | 13 | 1 | 0 | No | No |
| 18544302 | CARRIER FOR TARGETED DELIVERY TO A HOST | December 2023 | November 2024 | Allow | 11 | 0 | 1 | No | No |
| 18526938 | CORONAVIRUS VACCINE | December 2023 | October 2024 | Allow | 10 | 0 | 0 | Yes | No |
| 18512751 | INFLUENZA VIRUS HEMAGGLUTININ PROTEINS AND USES THEREOF | November 2023 | September 2024 | Allow | 10 | 0 | 0 | No | No |
| 18506851 | METHODS FOR PRODUCING GENETICALLY ENGINEERED CELL COMPOSITIONS AND RELATED COMPOSITIONS | November 2023 | September 2024 | Allow | 10 | 0 | 0 | No | No |
| 18504962 | UNIVERSAL VACCINE PLATFORM | November 2023 | November 2024 | Allow | 12 | 0 | 0 | No | No |
| 18492945 | ADENOVIRAL VECTORS ENCODING HEPATITIS B VIRAL ANTIGENS FUSED TO HERPES VIRUS GLYCOPROTEIN D AND METHODS OF USING THE SAME | October 2023 | September 2024 | Allow | 11 | 0 | 0 | No | No |
| 18493087 | METHODS AND SYSTEMS FOR ANALYSIS OF SAMPLES CONTAINING PARTICLES USED FOR GENE DELIVERY | October 2023 | September 2024 | Allow | 11 | 0 | 0 | No | No |
| 18490157 | Method of Conferring a Protective Immune Response to Norovirus | October 2023 | May 2025 | Abandon | 19 | 1 | 0 | No | No |
| 18462624 | MANUFACTURING OPTIMIZATION OF GL-2045, A MULTIMERIZING STRADOMER | September 2023 | September 2024 | Allow | 12 | 0 | 0 | No | No |
| 18461862 | PROTEIN-BASED NANOPARTICLE VACCINE FOR METAPNEUMOVIRUS | September 2023 | February 2025 | Allow | 18 | 1 | 0 | No | No |
| 18240748 | RNA SEPARATION AND RELATED TECHNIQUES FOR DETERMINING VIRUSES SUCH AS CORONAVIRUSES | August 2023 | May 2025 | Allow | 20 | 1 | 0 | Yes | No |
| 18458060 | BIVALENT, BISPECIFIC BINDING PROTEINS FOR PREVENTION OR TREATMENT OF HIV INFECTION | August 2023 | August 2024 | Allow | 12 | 0 | 0 | No | No |
| 18453418 | ANTI-DENGUE VIRUS ANTIBODIES, POLYPEPTIDES CONTAINING VARIANT FC REGIONS, AND METHODS OF USE | August 2023 | August 2024 | Allow | 12 | 0 | 0 | No | No |
| 18452698 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF HEPATITIS B INFECTION | August 2023 | September 2024 | Allow | 13 | 0 | 0 | No | No |
| 18452167 | HIV Treatment Compositions And Methods | August 2023 | March 2025 | Allow | 19 | 1 | 0 | No | No |
| 18450130 | Compositions and Methods for Altering Tissue Specificity and Improving AAV9-Mediated Gene Transfer | August 2023 | February 2025 | Abandon | 18 | 1 | 0 | No | No |
| 18227796 | PRE-IMMUNIZATION AND IMMUNOTHERAPY | July 2023 | March 2025 | Allow | 20 | 1 | 0 | No | No |
| 18347145 | METHODS TO IDENTIFY IMMUNOGENS BY TARGETING IMPROBABLE MUTATIONS | July 2023 | February 2025 | Abandon | 20 | 2 | 0 | No | No |
| 18346677 | USE OF ENDOGENOUS VIRAL VACCINE IN CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY | July 2023 | August 2024 | Allow | 13 | 0 | 0 | No | No |
| 18337734 | AUTOMATED PRODUCTION OF VIRAL VECTORS | June 2023 | August 2024 | Allow | 14 | 0 | 0 | No | No |
| 18338016 | METHODS AND COMPOSITION FOR GENE DELIVERY USING AN ENGINEERED VIRAL PARTICLE | June 2023 | August 2024 | Allow | 13 | 0 | 0 | No | No |
| 18337881 | Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus F proteins and their use | June 2023 | December 2024 | Allow | 18 | 1 | 0 | No | No |
| 18331811 | NUCLEIC ACID DETECTION USING TYPE III CRISPR COMPLEX | June 2023 | January 2025 | Abandon | 19 | 1 | 0 | No | No |
| 18322831 | INFLUENZA VACCINE | May 2023 | June 2024 | Allow | 12 | 0 | 0 | No | No |
| 18316829 | Method of Safe Administration of Phosphorylated TAU Peptide Vaccine | May 2023 | February 2025 | Allow | 21 | 1 | 0 | No | No |
| 18142624 | TESTING FOR PARTICULATES | May 2023 | June 2024 | Allow | 13 | 0 | 0 | No | No |
| 18118636 | VECTORS WITH MODIFIED INITIATION CODON FOR THE TRANSLATION OF AAV-REP78 USEFUL FOR PRODUCTION OF AAV | March 2023 | February 2025 | Abandon | 24 | 0 | 1 | No | No |
| 18114626 | OLIGOMERS AND OLIGOMER CONJUGATES | February 2023 | May 2024 | Allow | 15 | 0 | 0 | No | No |
| 18108148 | HIV PRE-IMMUNIZATION AND IMMUNOTHERAPY | February 2023 | November 2024 | Abandon | 21 | 1 | 0 | No | No |
| 18152930 | VIRUS-LIKE PARTICLES FOR PREVENTING THE SPREADING AND LOWERING THE INFECTION RATE OF VIRUSES | January 2023 | May 2024 | Allow | 16 | 1 | 0 | No | No |
| 17998856 | VACCINE COMPOSITIONS COMPRISING ENDOGENOUS GAG POLYPEPTIDES | November 2022 | February 2025 | Abandon | 27 | 1 | 0 | No | No |
| 17979280 | SYSTEM AND METHOD FOR CHARACTERIZING PROTEIN DIMERIZATION | November 2022 | August 2024 | Allow | 21 | 1 | 0 | No | No |
| 17935682 | VIRUS-LIKE NANOPARTICLES FOR ORAL DELIVERY | September 2022 | October 2024 | Allow | 25 | 1 | 0 | No | No |
| 17883031 | IMMUNOSTIMULATORY COMPOSITIONS | August 2022 | October 2024 | Allow | 26 | 1 | 0 | No | No |
| 17814401 | PEPTIDE-HLA COMPLEXES AND METHODS OF PRODUCING SAME | July 2022 | October 2024 | Allow | 27 | 1 | 0 | No | No |
| 17741894 | COMPOSITIONS AND METHODS FOR MAKING AND USING THERMOSTABLE IMMUNOGENIC FORMULATIONS WITH INCREASED COMPATIBILITY OF USE AS VACCINES AGAINST ONE OR MORE PATHOGENS | May 2022 | August 2024 | Allow | 28 | 1 | 0 | No | No |
| 17728798 | RECOMBINANT POLYPEPTIDES CONTAINING AT LEAST ONE IMMUNOGENIC FRAGMENT AND USES THEREOF | April 2022 | May 2025 | Allow | 36 | 0 | 0 | No | No |
| 17726801 | A SARS-CoV-2 FUSION PROTEIN VACCINE/REGIMEN | April 2022 | June 2025 | Allow | 37 | 0 | 0 | No | No |
| 17768624 | Dendritic Cell-Targeting Universal Vaccine for Influenza Infection | April 2022 | March 2025 | Allow | 35 | 0 | 0 | No | No |
| 17640395 | CANCER VACCINE | March 2022 | June 2025 | Allow | 39 | 0 | 0 | No | No |
| 17651973 | Trimer Stabilizing HIV Envelope Protein Mutation | February 2022 | March 2025 | Allow | 36 | 0 | 0 | No | No |
| 17635488 | CHARACTERIZATION OF GENE THERAPY VIRAL PARTICLES USING SIZE EXCLUSION CHROMATOGRAPHY AND MULTI-ANGLE LIGHT SCATTERING TECHNOLOGIES | February 2022 | April 2025 | Allow | 38 | 1 | 0 | No | No |
| 17573806 | VACCINE COMPOSITIONS FOR THE TREATMENT OF CORONAVIRUS | January 2022 | August 2025 | Abandon | 44 | 1 | 0 | No | No |
| 17616213 | SAPONIN CONJUGATE AND VACCINE OR PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | December 2021 | May 2025 | Allow | 41 | 1 | 0 | No | No |
| 17616413 | PRODUCTION METHOD FOR BIFURCATED LIPID-LINKED OLIGONUCLEOTIDE, AND INTERMEDIATE | December 2021 | February 2025 | Allow | 39 | 0 | 0 | No | No |
| 17610777 | VACCINIA VIRUS THAT INDUCES CELL FUSION AND USE THEREOF | November 2021 | July 2025 | Allow | 44 | 1 | 0 | No | No |
| 17453574 | TARGET SEQUENCE OF RNA VIRUS AND USE THEREOF | November 2021 | November 2024 | Allow | 36 | 1 | 1 | No | No |
| 17607720 | ENGINEERED T-CELLS CO-EXPRESSING AN ANTI-BCMA CAR AND AN ANTI-ECTOENZYME ANTIBODY AND THEIR USE IN THE TREATMENT OF CANCER | October 2021 | September 2025 | Abandon | 47 | 1 | 0 | No | No |
| 17511177 | HEPATITIS C VIRUS IMMUNOGENIC COMPOSITIONS AND METHODS OF USE THEREOF | October 2021 | January 2025 | Allow | 39 | 1 | 0 | No | No |
| 17469569 | ADENOVIRUS VECTORS AND METHODS FOR USING ADENOVIRUS VECTORS | September 2021 | November 2024 | Allow | 38 | 0 | 0 | No | No |
| 17379370 | Rapid Viral Assay | July 2021 | January 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17423565 | NANOPARTICLE-BASED INFLUENZA VIRUS VACCINES AND USES THEREOF | July 2021 | May 2025 | Allow | 46 | 2 | 1 | No | No |
| 17359064 | Methods, Compositions, and Systems for Detecting Coronavirus Neutralizing Antibodies | June 2021 | January 2025 | Allow | 43 | 1 | 1 | No | No |
| 17295152 | TAU PEPTIDE ANTIGENS AND ANTIBODIES BINDING THERETO FOR THE TREATMENT OF TAUOPATHIES | May 2021 | November 2024 | Abandon | 42 | 0 | 1 | No | No |
| 17291769 | NOVEL PORCINE ROTAVIRUS | May 2021 | March 2024 | Allow | 34 | 0 | 0 | No | No |
| 17211379 | COVID-19 VACCINE | March 2021 | May 2025 | Allow | 50 | 0 | 0 | No | No |
| 17191519 | CoV-2 (CoV-n) antibody neutralizing and CTL vaccines using protein scaffolds and molecular evolution | March 2021 | November 2024 | Abandon | 44 | 2 | 0 | Yes | No |
| 17151667 | USE OF MIR-132 AND MIR-212 IN PREPARATION OF DRUG FOR TREATING ADDICTION | January 2021 | August 2024 | Allow | 43 | 0 | 0 | No | No |
| 17059665 | Phosphorylated Polypeptide Antigen Vaccine, Preparation Method Therefor and Application Thereof | November 2020 | May 2025 | Allow | 54 | 1 | 1 | No | No |
No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.
Examiner CHESTNUT, BARRY A works in Art Unit 1671 and has examined 16 patent applications in our dataset. With an allowance rate of 75.0%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 43 months.
Examiner CHESTNUT, BARRY A's allowance rate of 75.0% places them in the 40% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by CHESTNUT, BARRY A receive 0.75 office actions before reaching final disposition. This places the examiner in the 5% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by CHESTNUT, BARRY A is 43 months. This places the examiner in the 16% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a -80.0% benefit to allowance rate for applications examined by CHESTNUT, BARRY A. This interview benefit is in the 0% percentile among all examiners. Note: Interviews show limited statistical benefit with this examiner compared to others, though they may still be valuable for clarifying issues.
When applicants file an RCE with this examiner, 25.0% of applications are subsequently allowed. This success rate is in the 38% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 100.0% of cases where such amendments are filed. This entry rate is in the 98% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants file petitions regarding this examiner's actions, 83.3% are granted (fully or in part). This grant rate is in the 86% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 3% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 3% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.